Presentation on Tuesday, June 24 at 12:30 p.m. Eastern Time
ANN ARBOR, Mich.--(BUSINESS WIRE)--
Esperion Therapeutics Inc. (NASDAQ: ESPR), a clinical stage
biopharmaceutical company focused on developing and commercializing
first-in-class, oral, low-density lipoprotein cholesterol (LDL-C)
lowering therapies for the treatment of patients with
hypercholesterolemia and other cardiometabolic risk markers, today
announced that president and chief executive officer, Tim M. Mayleben,
will present at the JMP Securities Healthcare Conference in New York
City, N.Y. on Tuesday, June 24 at 12:30 p.m. Eastern Time.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical
company focused on developing and commercializing first-in-class, oral,
LDL-cholesterol lowering therapies for the treatment of patients with
hypercholesterolemia and other cardiometabolic risk markers. ETC-1002,
Esperion's lead product candidate, is a unique, first-in-class, orally
available, once-daily small molecule designed to lower LDL-cholesterol
levels and avoid the side effects associated with therapies currently
available for lowering LDL-cholesterol. ETC-1002 is being developed
primarily for patients intolerant to statins and with elevated levels of
LDL-cholesterol. Phase 2b clinical trials for ETC-1002 are currently
underway and build upon the successful and comprehensive Phase 1 and
Phase 2a programs. For more information, please visit www.esperion.com
and follow us on Twitter at https://twitter.com/EsperionInc.
Media Contact:
W2O Group
Elliot Fox
212.257.6724
efox@w2ogroup.com
or
Investor
Contact:
Westwicke Partners
Jordan Kohnstam
443.450.4189
jordan.kohnstam@westwicke.com
Source: Esperion Therapeutics Inc.
News Provided by Acquire Media